sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations]) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency...

Home / Categories / Healthcare
Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations]) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Immunoglobulin Market by Application (Hypogammaglobulinemia,...
Report Code
RO1/113/1221

Publish Date
01/Jul/2017

Pages
220
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IMMUNOGLOBULIN

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. SIDE EFFECTS OF IMMUNOGLOBULIN TREATMENT
3.5. KEY FINDINGS

3.5.1. Top factors impacting
3.5.2. Top investment pockets

3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support activities

3.8. MARKET SHARE ANALYSIS, 2016
3.9. PRODUCT SCENARIO IN IMMUNOGLOBULIN MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. U.S.
3.10.2. Europe

3.10.2.1. France
3.10.2.2. Germany
3.10.2.3. Italy

3.10.3. China
3.10.4. Japan
3.10.5. India

3.11. INDICATIONS FOR IMMUNOGLOBULIN

3.11.1. U.S. FDA indications
3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.14. MARKET DYNAMICS

3.14.1. Drivers

3.14.1.1. Rise in prevalence of immunodeficiency diseases
3.14.1.2. Increase in adoption of immunoglobulin
3.14.1.3. Increase in incidence of bleeding disorders
3.14.1.4. Surge in geriatric population

3.14.2. Restraints

3.14.2.1. Stringent government regulations
3.14.2.2. High cost of therapy

3.14.3. Opportunities

3.14.3.1. Opportunities in emerging economies
3.14.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4 IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. PRIMARY IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

CHAPTER 5 IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. OVERVIEW
5.2. IGG

5.2.1. Key market trends
5.2.2. Clinical interpretations

5.3. IGA

5.3.1. Key market trends
5.3.2. Clinical interpretation

5.4. IGM

5.4.1. Key market trends
5.4.2. Clinical interpretation

5.5. IGE

5.5.1. Key market trends
5.5.2. Clinical Interpretation

5.6. IGD

5.6.1. Key market trends
5.6.2. Clinical interpretations

CHAPTER 6 IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. INTRAVENOUS MODE OF DELIVERY

6.2.1. Key market trends
6.2.2. Market size and forecast
6.2.3. 5% concentration

6.2.3.1. Market size and forecast

6.2.4. 10% concentration

6.2.4.1. Market size and forecast

6.2.5. Other concentrations

6.2.5.1. Market size and forecast

6.3. SUBCUTANEOUS MODE OF DELIVERY

6.3.1. Key market trends
6.3.2. Market size and forecast
6.3.3. 16.5% concentration

6.3.3.1. Market size and forecast

6.3.4. 20% concentration

6.3.4.1. Market size and forecast

6.3.5. Other concentrations

6.3.5.1. Market size and forecast

CHAPTER 7 IMMUNOGLOBULIN MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Market size and forecast
7.2.3. North America IVIG market

7.2.3.1. Market size and forecast

7.2.4. North America SCIG market

7.2.4.1. Market size and forecast

7.2.5. U.S.

7.2.5.1. Market size and forecast
7.2.5.2. U.S. IVIG market size and forecast
7.2.5.3. U.S. SCIG market size and forecast

7.2.6. Canada

7.2.6.1. Market size and forecast
7.2.6.2. Canada IVIG market size and forecast
7.2.6.3. Canada SCIG market size and forecast

7.2.7. Mexico

7.2.7.1. Market size and forecast
7.2.7.2. Mexico IVIG market size and forecast
7.2.7.3. Mexico SCIG market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Market size and forecast
7.3.3. Europe IVIG market

7.3.3.1. Market size and forecast

7.3.4. Europe SCIG market

7.3.4.1. Market size and forecast

7.3.5. UK

7.3.5.1. Market size and forecast
7.3.5.2. UK IVIG market size and forecast
7.3.5.3. UK SCIG market size and forecast

7.3.6. France

7.3.6.1. Market size and forecast
7.3.6.2. France IVIG market size and forecast
7.3.6.3. France SCIG market size and forecast

7.3.7. Germany

7.3.7.1. Market size and forecast
7.3.7.2. Germany IVIG market size and forecast
7.3.7.3. Germany SCIG market size and forecast

7.3.8. Italy

7.3.8.1. Market size and forecast
7.3.8.2. Italy IVIG market size and forecast
7.3.8.3. Italy SCIG market size and forecast

7.3.9. Austria

7.3.9.1. Market size and forecast
7.3.9.2. Austria IVIG market size and forecast
7.3.9.3. Austria SCIG market size and forecast

7.3.10. Russia

7.3.10.1. Market size and forecast
7.3.10.2. Russia IVIG market size and forecast
7.3.10.3. Russia SCIG market size and forecast

7.3.11. Rest of Europe

7.3.11.1. Market size and forecast
7.3.11.2. Rest of Europe IVIG market size and forecast
7.3.11.3. Rest of Europe SCIG market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Market size and forecast
7.4.3. Asia-Pacific IVIG market

7.4.3.1. Market size and forecast

7.4.4. Asia-Pacific SCIG market

7.4.4.1. Market size and forecast

7.4.5. Australia

7.4.5.1. Market size and forecast
7.4.5.2. Australia IVIG market size and forecast
7.4.5.3. Australia SCIG market size and forecast

7.4.6. China

7.4.6.1. Market size and forecast
7.4.6.2. China IVIG market size and forecast
7.4.6.3. China SCIG market size and forecast

7.4.7. Japan

7.4.7.1. Market size and forecast
7.4.7.2. Japan IVIG market size and forecast
7.4.7.3. Japan SCIG market size and forecast

7.4.8. India

7.4.8.1. Market size and forecast
7.4.8.2. India IVIG market size and forecast
7.4.8.3. India SCIG market size and forecast

7.4.9. Rest of Asia-Pacific

7.4.9.1. Market size and forecast
7.4.9.2. Rest of Asia-Pacific IVIG market size and forecast
7.4.9.3. Rest of Asia-Pacific SCIG market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Market size and forecast
7.5.3. LAMEA IVIG market

7.5.3.1. Market size and forecast

7.5.4. LAMEA SCIG market

7.5.4.1. Market size and forecast

7.5.5. Brazil

7.5.5.1. Market size and forecast
7.5.5.2. Brazil IVIG market size and forecast
7.5.5.3. Brazil SCIG market size and forecast

7.5.6. Argentina

7.5.6.1. Market size and forecast
7.5.6.2. Argentina IVIG market size and forecast
7.5.6.3. Argentina SCIG market size and forecast

7.5.7. Turkey

7.5.7.1. Market size and forecast
7.5.7.2. Turkey IVIG market size and forecast
7.5.7.3. Turkey SCIG market size and forecast

7.5.8. Saudi Arabia

7.5.8.1. Market size and forecast
7.5.8.2. Saudi Arabia IVIG market size and forecast
7.5.8.3. Saudi Arabia SCIG market size and forecast

7.5.9. Rest of LAMEA

7.5.9.1. Market size and forecast
7.5.9.2. Rest of LAMEA IVIG market size and forecast
7.5.9.3. Rest of LAMEA SCIG market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. BAXTER INTERNATIONAL INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. CSL LTD.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments

8.3. GRIFOLS S.A.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. OCTAPHARMA AG

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments

8.5. KEDRION BIOPHARMA INC.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. LFB GROUP

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Key strategic moves and developments

8.7. BIOTEST AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. CHINA BIOLOGICS PRODUCTS, INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. BDI PHARMA INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. BAYER HEALTHCARE

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com